GLG News by Lexapro Prescribers: Psychiatrists (US)

The push for FDA approval of Lexapro into the adolescent depression market could significantly impact sales of this already successful medication.

An FDA draft proposal regarding off-label drug promotion, if approved and implemented, could be a boon to both pharmaceutical companies and physicians...and ultimately to patients as well.

PRISTIQ, the single isomer form of Effexor, has performed well in a Phase III study, done in response to an FDA approvable letter earlier this year.  When launched it will change the balance of antidepressants prescribed for major depressive disorder.  

On November 26 Schering-Plough Corporation (NYSE: SGP) announced the acceptance of the New Drug Application (NDA) for asenapine by the U.S. Food and Drug Administration (FDA). Schering-Plough is seeking marketing approval from the FDA for the treatment of schizophrenia and acute mania or mixed episodes...

Forest Laboratories, Inc (NYSE:FRX) and Gedeon Richter announced preliminary top line results from a Phase II-B ranomized, double-blind placebo-controlled, 6 week study of RGH-188 for the acute treatment of schizophrenia in 389 patients. These results have prompted the companies to announce their intentions...

1. Iloperidone has demonstrated efficacy in treating positive and negative symptoms of schizophrenia and also has a favorable safety profile. 2. Vanda has utilized pharmacogenetic studies to identify a group of schizophrenic patients that will benefit from this agent that binds to a number of serotonin...

The announcement of Eli Lilly’s (NYS:LLY) successful proof of concept study with LY2140023 in patients with schizophrenia represents a new milestone in the pharmacological treatment of schizophrenia and related psychotic disorders. Not since the introduction of thorazine or risperidone have we witnessed...

This intriguing use for Super Glue (actually Dermabond...JNJ) suggests that there may be other uses for agents traditionally not thought of as mainstream dental or medical treatments....perhaps we need to expand our thinking...especially in emergency settings and, perhaps, beyond as well.

1. DOV 21,947 in a phase Ib study produced a statistically significant reduction in plasma triglyceride levels, body weight, and Body Mass Index (BMI). 2. This compound is believed to not only manage depression but also impact weight gain. 3. A phase II study of DOV 21,947 is being delayed until the...

Lilly is currently leader in Psychiatry with 4 active medications with great marketing for Psychiatry and Primary care physician. New compound that has a unique mechanism on Metabotropic Glutamate 2/3 Receptors, can work on Schizophrenia and other Psychiatric diagnosis. This is great opportunity...